Skip to content

DOCTOR Compare - A Study in the DOCTOR Series (Does Optical Coherence Tomography Optimize Revascularization?

Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Metallic Stents and Bioresorbable Vascular Scaffolds - DOCTOR Compare

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02237456
Enrollment
11
Registered
2014-09-11
Start date
2014-07-31
Completion date
2014-09-30
Last updated
2015-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Coronary Disease, Myocardial Infarction

Keywords

Myocardial infarction, Atherosclerosis, PCI, OCT, Optical coherence tomography, Stent, Bioresorbable stents

Brief summary

The purpose of this study is to compare optical coherence tomography (OCT) scans performed in the same coronary artery with two different OCT systems (Lunawave and OPTIS) before and after implantation of stents or bioresorbable scaffolds.

Detailed description

Standard treatment of persons with narrowings of the heart's coronary artery is balloon treatment with implantation of stents (Percutaneous coronary intervention (PCI )). To evaluate disease in coronary arteries prior to, and during PCI , X-ray fluoroscopy with contrast is used. X-ray fluoroscopy produces little information of any disease changes in the vessel wall and implanted stents and especially polylactid acid (PLA) type bioresorbable scaffolds are visualized poorly . Optical coherence tomography (OCT) is a light-based, high resolution, imaging modality for intra coronary assessment of tissue and implants. Currently two CE-marked OCT systems are used in clinical practice in (Illumien OPTIS, St. Jude Medical , Minnesota, USA and Lunawave, Terumo , Tokyo, Japan). It is a common assumption that the scanning images for the two systems are similar and are interpreted the same way. The aim of the study is to assess if tissue, stents and PLA type scaffolds are presented with same characteristics by the two systems. Same segment scans by the two systems will be systematically compared and reported. Differences in scans by the two systems may have implications for the interpretation and thus may affect clinical decisions.

Interventions

PROCEDUREComparison of OCT scans
PROCEDUREComparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare

Sponsors

Aarhus University Hospital Skejby
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Indication for intervention with PCI on the right or left coronary artery * Age \>18 years * Must be able to give written informed consent

Exclusion criteria

* Expected life span of less than one year * Pregnancy or possible pregnancy * Cardiogenic shock * Especially tortuous vessels * Renal impairment (creatinine\> 100 micromoles / L)

Design outcomes

Primary

MeasureTime frame
Characteristics of the fibrous cap (minimum thickness)Baseline
Comparison of quantitative and semi-quantitative tissue analysis obtained with OCT imagesBaseline
Characteristics of thrombic mass (average thickness of signal-rich area, shade degree)Baseline
Characteristics of fibrous tissue (maximum scan penetrance)Baseline
Characteristics of lipid plaque (signal intensities under the fibrous cap)Baseline
Characteristics of calcium plaque (matched calcium plaques that can be quantified for sizes)Baseline
Characteristics of vessel dissection (exploratory)Baseline

Secondary

MeasureTime frameDescription
Detection of stent strutsBaselineStent evaluation obtained by Lunawawe recordings versus OPTIS recordings (including areas with thrombus, plaque, bare metal stent, bioresorbable stents, 3D reconstruction of stents (qualitative and quantitative assessment of stent visualization degree)

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026